Arrowhead Pharmaceuticals, Inc. $ARWR Shares Bought by Boothbay Fund Management LLC

Boothbay Fund Management LLC increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 34.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 83,388 shares of the biotechnology company’s stock after purchasing an additional 21,441 shares during the quarter. Boothbay Fund Management LLC owned about 0.06% of Arrowhead Pharmaceuticals worth $2,876,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Ameriprise Financial Inc. increased its stake in Arrowhead Pharmaceuticals by 2.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 274,163 shares of the biotechnology company’s stock valued at $9,456,000 after buying an additional 7,136 shares during the period. Schonfeld Strategic Advisors LLC lifted its stake in shares of Arrowhead Pharmaceuticals by 12.8% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 543,916 shares of the biotechnology company’s stock worth $18,760,000 after acquiring an additional 61,861 shares during the period. Creative Planning lifted its stake in shares of Arrowhead Pharmaceuticals by 13.9% in the 3rd quarter. Creative Planning now owns 52,006 shares of the biotechnology company’s stock worth $1,794,000 after acquiring an additional 6,344 shares during the period. Raymond James Financial Inc. boosted its holdings in shares of Arrowhead Pharmaceuticals by 33.9% in the third quarter. Raymond James Financial Inc. now owns 227,269 shares of the biotechnology company’s stock valued at $7,839,000 after acquiring an additional 57,521 shares in the last quarter. Finally, Amundi boosted its holdings in shares of Arrowhead Pharmaceuticals by 11.8% in the third quarter. Amundi now owns 28,156 shares of the biotechnology company’s stock valued at $1,056,000 after acquiring an additional 2,962 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ARWR shares. Royal Bank Of Canada upped their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. The Goldman Sachs Group lifted their price target on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, January 7th. Weiss Ratings raised Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, February 6th. HC Wainwright restated a “buy” rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 10th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $110.00 target price (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.67.

Arrowhead Pharmaceuticals Trading Up 4.2%

Arrowhead Pharmaceuticals stock opened at $57.37 on Tuesday. The firm has a market cap of $8.03 billion, a price-to-earnings ratio of 37.50 and a beta of 1.23. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $9.57 and a 1 year high of $76.76. The firm’s 50 day moving average price is $64.34 and its two-hundred day moving average price is $51.82. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The company had revenue of $264.03 million for the quarter, compared to analyst estimates of $225.66 million. During the same quarter last year, the company posted ($1.39) EPS. Arrowhead Pharmaceuticals’s revenue was up 10461.3% on a year-over-year basis. On average, research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Insider Activity

In related news, Director Adeoye Y. Olukotun sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $67.66, for a total value of $676,600.00. Following the completion of the sale, the director owned 33,600 shares in the company, valued at approximately $2,273,376. This represents a 22.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mauro Ferrari sold 7,530 shares of the firm’s stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $70.00, for a total transaction of $527,100.00. Following the completion of the transaction, the director directly owned 69,053 shares of the company’s stock, valued at $4,833,710. This represents a 9.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 311,538 shares of company stock worth $20,411,342. 3.60% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.